News & Events

You are here


Novotech signs MOU with South Korea’s leading medical center, the Asan Medical Center


15 April 2017, Sydney, Australia and Seoul, Korea: Asia Pacific specialist CRO Novotechannounced today it has signed a Memorandum of Understanding (MOU) with South Korea’s largest medical institution – The...


New Frost & Sullivan research reveals Asia as Preferred Destination for Clinical Trials


1 March 2017, Sydney, Australia: Frost & Sullivan today released its latest white paper, ‘Asia: Preferred Destination for Clinical Trials’, with Asia Pacific specialist CRO Novotech. Research...


8 reasons why China should be your next clinical trial destination

Happy Chinese New Year!           

While China has long been a key power house in Asia, its trajectory over the next decade is set to sky rocket.

Here are 8 top facts you need to...


8 reasons why Australia should be your next clinical trial destination

Australia is internationally recognised for its superior clinical research and healthcare infrastructure, world-class research capabilities and highly skilled researchers. All...


Novotech & Deloitte brief biotech companies on benefits of accessing Australia’s R&D scheme

At this year’s JP Morgan conference, Novotech & Deloitte briefed international biotech companies on how to access ...


Novotech Presents to Chinese Biotechs on Key Benefits of Early Stage Clinical Trials in Australia

Novotech presented to a number of biotechnology companies based at China’s SuZhou BioBay industrial park, on accessing...


Novotech Recognized as Asia Pacific Growth Leader by Frost & Sullivan Research Analysts

Novotech has won the Clinical Research Organisation (CRO) Growth Excellence Leadership award in Frost & Sullivan’s Best Practice Awards for 2016.



Novotech announces transition of CEO role

Novotech announces transition of CEO role from Alek Safarian to John Moller, effective 23rd January 2017.

Currently based in Novotech’s Singapore office, Dr Moller joined Novotech as Chief Operating Officer, Asia, in...


Novotech and Deloitte Launch U.S. Biotech Briefings about 60% Savings for Early Phase Clinical Trials in Australia

Sydney, Australia – October 27, 2016 In an industry first Novotech and Deloitte have teamed up to brief U.S. CFOs of early stage companies about Australian tax breaks for early phase clinical trials. New research from Frost & Sullivan shows...


Download Whitepaper - Australia: Preferred Destination for Early Phase Clinical Trials (A Frost and Sullivan White Paper)


Click here to download the Frost and Sullivan whitepaper to learn more about the benefits of running early phase trials in Australia.